AbbVie recently received FDA approvals for Decnupaz and Skinvive by Juvederm, enhancing its product portfolio. The company also reported positive Phase 3 trial results for chronic lymphocytic leukemia treatment, supporting future oncology growth. Additionally, AbbVie's drug Venclexta generated $770 million in Q1 revenue, marking significant year-over-year and quarterly increases. These developments reinforce AbbVie's strong position in immunology and oncology markets despite competitive pressures.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
